PM CDT at the ASCO Annual MeetingMIAMI, April 24, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) ...

Session: Rapid Oral Abstract Sessions: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology ...

Cancer patients invariably develop resistance to targeted drugs, so drugmakers develop strategies to combat it before ...

On 16 April 2025, the European Commission (EC) published a press release announcing the launch of and details regarding the ...

Anaplastic thyroid cancer (ATC), a rare yet highly aggressive malignancy, continues to represent a major clinical challenge. A recent review published in Genes & Diseases offers a comprehensive ...

Shares of Pasithea Therapeutics Corp. (KTTA) surged nearly 47% on Thursday, closing at a two-month high, after an external ...

Verastem, Inc.'s priority PDUFA date for avutometinib + defactinib in LGSOC set for June 2025; explore future data updates. Click for my VSTM stock update.

Following recent US Food and Drug Administration approvals for targeted anti-BRAF/anti-MEK inhibitors dabrafenib and trametinib and immunotherapy agents nivolumab and pembrolizumab, these ...

Calcitonin gene-related peptide (CGRP) inhibitors are now considered a first-line treatment used to treat and prevent migraines. There are two types of CGRP medications: monoclonal antibodies and ...